

Index

- ¹³C-urea breath test, 97
 24-h intragastric pH, 381
 24-h profile of plasma pepsinogen I, 389
 24-h profile of plasma pepsinogen II, 389
 24-h profile of plasma gastrin, 389
 5-aminosalicylic acid, 261, 671
 5-ASA, 51
 5-ASA compounds, 647
 5-HT₁-like agonist, 685
 α -adrenoreceptors, 415
 α -adrenoreceptor agonist, 125, 253
 α -adrenoreceptor antagonist, 125, 253
 Aabakken, L., Review article: non-steroidal, anti-inflammatory drugs—the extending scope of gastrointestinal side effects, 143
 abdominal symptoms, 437
 absorption, 701
 acetorphan, 305
 acetyl-5-aminosalicylic acid, 671
 achalasia, 507
 acid, 707
 acid inhibition, 381
 acid secretion, 291, 359, 407
 acidity, 373
 adverse reactions, 609
 Africa, 119
 Alberola, B. *see* Cortot, A.
 alcohol low-dose 0.15 g/kg, 269
 alcohol withdrawal, 541
 alcoholic cirrhosis, 541
 alcoholic hepatitis, 541
 alcoholic liver disease, 541
 alginate, 579
 allergic, 51
 aluminium salts, 447
 ammonia, 659
 ammonium, 659
 Annibale, B. *see* Delle Fave, G.
 antacid, 119, 181, 447, 579
 antacid in-vitro evaluation, 447
 antibiotics, 291
 antioxidant therapy, 231
 antisecretory, 189
 arachidonic acid, 165
 Ardrill, J. E. S. *see* Fullarton, G. M.
 Arnold, J. *see* Swift, G. L.
 artificial duodenum, 447
 artificial stomach, 447
 aspirin, 707
 Astier, A. *see* Petitjean, O.
 atenolol, 701
 Ayesu, K. *see* Moss, S. F.
 Aziz, K. *see* Dakkak, M.
 β -adrenoreceptor agonist, 123, 253
 β -adrenoreceptor antagonist, 123, 253
 β -carotene, 231
 Back, D. J. *see* Grimmer, S. F. M.
 balsalazide, 479, 647
 Barish, C. *see* Roufail, W.
 Baron, J. H. *see* Gaffer, M. H.
 Barrison, I. G. *see* Gaffer, M. H.
 Baumer, P. *see* Bergmann, J. F.
 Beattie, S. *see* Patchett, S.
 Bell, G. D. *see* Weil, J.
 Bell, G. D., Powell, K., Burrridge, S. M., Harrison, G., Weil, J., Gant, P. W., Jones, P. H., Trowell, J. E., Does a previous course of tripotassium dicitrate bismuthate affect the subsequent chances of successful *Helicobacter pylori* eradication?, 327
 Bell, G. D., Powell, K., Burrridge, S. M., Pallearos, A., Jones, P. H., Gant, P. W., Harrison, G., Trowell, J. E., Experience with 'triple' anti-*Helicobacter pylori* eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance, 427
 Bell, G. D., Powell, K., Burrridge, S. M., Spencer, G., Bolton, G., Purser, K., Brooks, S., Prosser, S., Harrison, G., Gant, P. W., Jones, P. H., Trowell, J. E., Short report: omeprazole plus antibiotic com-

- binations for the eradication of metronidazole-resistant *Helicobacter pylori*, 751
- Belsito, A. *see* Roufail, W.
- Benati, G. *see* Corazza, G. R.
- Bendtzen, K. *see* Langholz, E.
- Bennett, A. *see* Swift, G. L.
- Bennett, J. R. *see* Dakkak, M.
- Bergmann, J. F., Chaussade, S., Couturier, D., Baumer, P., Schwartz, J. C., Lecomte, J. M., Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers, 305
- Beukers, R., De Rave, S., Van Den Berg, J. W. O., Schalm, S. W., Oral pharmacokinetics of cyclosporin in patients with primary biliary cirrhosis and patients with skin diseases, 459
- Bibbey, D. *see* Haines, D. J.
- Binder, V. *see* Langholz, E.
- bioavailability, 351
- bismuth, 97, 119, 291
- bismuth salicylate, 97
- bismuth subnitrate, 97
- Black, D. L. *see* Bluhm, R. E.
- bleeding, 707
- Blendis, L. M., Review article: the treatment of alcoholic liver disease, 541
- blood loss, 67
- Blower, P. R. *see* Melarange, R.
- Bluhm, R. E., Rodgers, W. H., Black, D. L., Wilkinson, G. R., Branch, R. A., Cholestasis in transplant patients—what is the role of cyclosporin, 207
- Bolton, G. *see* Bell, G. D.
- Boswell, D. J. *see* Greenfield, S. M.
- Bottiglier, T. *see* Uden, S.
- bowel preparation, 513
- Boyd, E. J. S., Penston, J. G., Wormsley, K. G., Maintenance therapy in duodenal and gastric ulcer disease: survey of practice amongst British gastroenterologists, 727
- Braganza, J. M., *see* Uden, S.
- Branch, R. A. *see* Bluhm, R. E.
- breath hydrogen, 61
- Brenna, E., Waldum, H. L., Sandvik, A. K., Schulze Sögnen, B., Kristensen, A., Effects on the rat oxyntic mucosa of the histamine₂-antagonist loxidine and the H⁺, K⁺-ATPase inhibitor omeprazole, 335
- Brooks, S. *see* Bell, G. D.
- Broom, C. *see* Hannan, A.
- Brown, P. *see* Green, J. R. B.
- Brundell, S. *see* Cole, A. T.
- Brynskov, J. *see* Langholz, E.
- Buchler, M. *see* Kemmer, T. P.
- Burget, D. W. *see* Chiverton, S. G.
- Burnham, W. R. *see* McIntyre, A. S.
- Burridge, S. M. *see* Bell, G. D.
- Byers, C. A. *see* Morrison, G.
- Calam, J. *see* Moss, S. F.
- calcium, 399
- calcium channel blockade, 165
- Calza, G. *see* Corazza, G. R.
- carcinoid syndrome, 273
- Carnaby, S. *see* Hunt, J. B.
- Cassetta, M. R. *see* Delle Fave, G.
- cefprozil, 503
- cephalosporin, 503
- Chagas' disease, 507
- Chaussade, S. *see* Bergmann, J. F.
- Chiverton, S. G., Howden, C. W., Burget, D. W., Hunt, R. H., Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration, 103
- cholestasis, 209
- cimetidine, 181, 223, 315, 693, 701
- Clark, M. L. *see* Hunt, J. B.
- Classen, M. *see* Madaus, S.
- clinical trial, 181, 503
- Coates, M. E. *see* Melarange, R.
- coeliac disease, 79
- colalamin, 399
- Cole, A. T., Brundell, S., Hudson, N., Hawthorne, A. B., Mahida, Y. R., Hawkey, C. J., Ranitidine: differential effects on gastric bleeding and mucosal damage induced by aspirin, 707
- colitis, ulcerative, 165
- colon, 701
- colonic motility, 589
- colonoscopy, 513
- combination treatment, 189
- contraceptive steroids, 79
- conventional and germ-free rats, 67
- Corazza, G. R., Benati, G., Sorge, M., Stocchi, A., Calza, G., Gasbarrini, G., β -Galactosidase from *Aspergillus niger* in adult lactose malabsorption: a double-blind crossover study, 61
- corticosteroids, 541
- Cortot, A., Guillemot, F., Moreau, J., Soule, J. C., Veyrac, M., Alberola, B., Pappo, M., Influence of the timing of administration of 300 mg ranitidine on 24-hour gastric pH in patients with acute duodenal ulcer, 487
- Couturier, D. *see* Bergmann, J. F.
- Crean, 549
- Crohn's disease, 495

- cyclosporin, 495
cyclosporine, 209, 459
cystic fibrosis, 549
cytoprotection, 707
- Dakkak, M., Aziz, K., Bennett, J. R., Short report: comparison of two orally administered bowel preparations for colonoscopy—polyethylene glycol and sodium picosulphate, 513
Davies, G. S. R. *see* Gaffer, M. H.
Day, G. M. *see* Sanders, S. W.
Day, J. P. *see* Uden, S.
De Rave, S. *see* Beukers, R.
De-Noltabs, 97
delayed release indomethacin, 717
Delle Fave, G., Annibale, B., Franceschi, M., Quatrini, M., Cassetta, M. R., Torsoli, A., Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease, 469
Ditschuneit, H. *see* Kemmer, T. P.
Dodge, J. A. *see* Morrison, G.
domperidone, 223
double-blind study, 87
drug, 701
drug therapy, 181
duodenal pH, 447
duodenal ulcer, 87, 113, 171, 253, 315, 469, 487, 659, 727
- eicosanoids, 165
Ellis, A. *see* Grimmer, S. F. M.
endoscopy sedation, 745
enterochromaffin-like cell, 335
eradication of *H. Pylori*, 389
erosive oesophagitis, 597
erythromycin, 589, 751
ethanol absorption, 693
ethinyloestradiol metabolism, 79
Eudragit, 31
Evans, B. K. *see* Swift, G. L.
Evans Jr, D. J. *see* Graham, D. Y.
exocrine pancreas, 41
- Fairclough, P. D. *see* Hunt, J. B.
famotidine, 87, 469, 693
Farthing, M. J. G. *see* Hunt, J. B.
Farup, P. G., Compliance with anti-ulcer medication during short-term healing phase clinical trials, 179
Feldman, M., Goldschmidt, M., Effect of potassium chloride on gastric acid secretion and gastrin release in humans, 407
Fenn, G. C., Correspondence, 654
Festen, H. *see* Pounder, R. E.
- Figueiredo, M. C. A., Oliveira, R. B., Iazigi, N., Matsuda, N. M., Short report: comparison of the effects of sublingual nifedipine and isosorbide dinitrate on oesophageal emptying in patients with Chagasic achalasia, 507
Flogerzi, B. *see* Schuerer-Maly, C.-C.
flumazenil, 745
fluorescent polarization immunoassay, 209
Ford, G. A., Oliver, P. S., Shepherd, N. A., Wilkinson, S. P., A Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use, 31
four and eight weeks of healing, 609
Fowler, P. *see* Houghton, L. A.
Franceschi, M. *see* Delle Fave, G.
Fraser, A. G. *see* Prewett, E. J.
Fraser, A. G., Hudson, M., Sawyerr, A. M., Rosalki, S. B., Pounder, R. E., Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol, 267
Fraser, A. G., Hudson, M., Sawyerr, A. M., Smith, M., Rosalki, S. B., Pounder, R. E., Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal, 693
Fraser, A. G., Prewett, E. J., Pounder, R. E., Samloff, I. M., Short report: twenty-four-hour hyperpepsinogenaemia in *Helicobacter pylori*-positive subjects is abolished by eradication of the infection, 389
free radicals, 231
Friess, H. *see* Kemmer, T. P.
frusemide, 701
Fullarton, G. M., Ardill, J. E. S., McColl, K. E. L., The effect of H₂-blockade on plasma gastrin concentration in patients with an achlorhydric stomach, 557
fungal β -galactosidase added milk, 61
fusidic acid, 495
- Gant, P. W. *see* Bell, G. D.
Gasbarrini, G. *see* Corazza, G. R.
gastric acid, 253, 487
gastric acid secretion, 197
gastric alcohol dehydrogenase, 693
gastric emptying, 223, 447
gastric pH, 189, 487
gastric ulcer, 727
gastrin, 103, 197, 373, 407, 469
gastritis, antral, 253, 291
gastro-oesophageal reflux, 273, 579
gastro-oesophageal reflux disease, 565, 597
gastrointestinal damage, 67
gastrointestinal motility, 125

- gastrointestinal secretion, 125
 gastrointestinal symptoms, 223
 gastroparesis, 273
 gastropathy, 717
- Gertner, D. J., Rampton, D. S., Stevens, T. R. J., Lennard-Jones, J. E., Verapamil inhibits in-vitro leucotriene B₄ release by rectal mucosa in active ulcerative colitis, 163
- Giaffer, M. H., Holdsworth, C. D., Lennard-Jones, J. E., Rodrigues, C. A., McIntyre, P. B., Manjunatha, S., Baron, J. H., Barrison, I. G., Polson, R. J., Hoare, A. M., Davies, G. S. R., Thornton, P. C., Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day, 479
- Giaffer, M. H., O'Brien, C. J., Holdsworth, C. D., Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine, 51
- Gibson, J. A. *see* Green, J. R. B.
- Gibson, R. *see* Kendall, M. J.
- Gilmore, I. T. *see* Grimmer, S. F. M.
- Glaxo Erosive Esophagitis Study Group *see* Roufail, W.
- Go, M. F. *see* Graham, D. Y.
- Goldschmiedt, M. *see* Feldman, M.
- Graham, D. Y., *see* Malaty, H.
- Graham, D. Y., Correspondence, 653
- Graham, D. Y., Go, M. F., Evans Jr, D. J., Review article: urease, gastric ammonium/ammonia, and *Helicobacter pylori*: the past, the present, and recommendations for future research, 659
- granisetron, 273
- Greaves, J. L. *see* Washington, N.
- Green, J. R. B. *see* Haines, D. J.
- Green, J. R. B., Swan, C. H. J., Rowlinson, A., Gibson, J. A., Brown, P., Kerr, G. D., Swarbrick, E. T., Thornton, P., Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months, 647
- Greenfield, S. M., Boswell, D. J., Punchard, N. A., Thompson, R. P. H., The effects of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid on lipid peroxidation in erythrocytes and prostaglandin production by mononuclear cells, 671
- Greski, P. A. *see* Sanders, S. W.
- Grimmer, S. F. M., Back, D. J., L'E Orme, M., Tjia, J. F., Gilmore, I. T., Ellis, A., The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease, 79
- Grose, R. D., Hayes, P. C., Review article: the pathophysiology and pharmacological treatment of portal hypertension, 521
- Grymbowski, T. *see* Hotz, J.
- Guilford, S. A. *see* Morrison, G.
- Guillemot, F. *see* Cortot, A.
- H⁺K⁺-ATPase inhibitors, 197
- H₂-antagonists, 381
- H₂-receptor antagonists, 597
- H. pylori* eradication, 427
- haemodynamics, 521
- Hage, E. *see* Hendel, L.
- Haines, D. J., Bibbey, D., Green, J. R. B., The effects of flumazenil on alertness and hypoxia in elderly patients after ERCP, 745
- Halter, F. *see* Schuerer-Maly, C.-C.
- Hannan, A., Weil, J., Broom, C., Walt, R. P., Effects of oral pantoprazole on 24-hour intragastric acidity and plasma gastrin profiles, 373
- Harrison, G. *see* Bell, G. D.
- Hawkey, C. J. *see* Cole, A. T.
- Hawthorne, A. B. *see* Cole, A. T.
- Hayes, P. C. *see* Grose, R. D.
- heartburn relief, 597
- Heatley, R. V., Review article: the treatment of *Helicobacter pylori* infection, 291
- Helicobacter pylori*, 97, 113, 119, 171, 253, 291, 327, 389, 659, 757
- Helicobacter pylori* therapy, 503
- Hendel, J. *see* Hendel, L.
- Hendel, L., Hage, E., Hendel, J., Stentoft, P., Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis, 565
- Hennig, U. *see* Hotz, J.
- Henry, M. M. *see* Jameson, J. S.
- hepatotoxicity, 209
- high performance liquid chromatography, 209
- histamine, 335
- Hoare, A. M. *see* Giaffer, M. H.
- Holcombe, C., Thom, C., Kaluba, J., Lucas, S. B., *Helicobacter pylori* clearance in the treatment of non-ulcer dyspepsia, 119
- Holdsworth, C. D. *see* Giaffer, M. H.
- Hotz, J., Kleinert, R., Grymbowski, T., Hennig, U., Schwarz, J. A., Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration, 87
- Houghton, L. A., Fowler, P., Keene, O. N., Read, N. W., Effect of sumatriptan, a new selective 5HT₁-like agonist, on liquid gastric emptying in man, 685
- Howden, C. W. *see* Chiverton, S. G.

- Hoyos, P. A. *see* Sanders, S. W.
Hudson, M. *see* Fraser, A. G.
Hudson, N. *see* Cole, A. T.
human gastrointestinal transit, 415
human jejunum, 619
Hunt, R. H. *see* Chiverton, S. G.
Hunt, J. B., Thillainayagam, A. V., Carnaby, S., Fairclough, P. D., Clark, M. L., Farthing, M. J. G., A new model of human secretory diarrhoea using cholera toxin, 619
hydrochlorothiazide, 701
hydrocortisone, 357
hyperbilirubinaemia, 209
hypergastrinaemia, 197, 335
- Iazigi, N. *see* Figueiredo, M. C. A.
Iftikhar, S. Y. *see* Washington, N.
Iishi, H. *see* Tatsuta, M.
indomethacin, 453, 717
inflammatory bowel disease, 51, 165
interleukin-1, 495
interleukin-2, 495
intestinal perfusion, 619
intestinal secretion, 619
intragastric acidity, 103
irritable bowel syndrome, 273
isosorbide dinitrate, 507
- Jameson, J. S., Kapadia, S. A., Polson, R. J., McCarthy, P. T., Misiewicz, J. J., Is oropharyngeal anaesthesia with topical lignocaine useful in upper gastrointestinal endoscopy?, 739
Jameson, J. S., Rogers, J., Misiewicz, J. J., Raimundo, A. H., Henry, M. M., Oral or intravenous erythromycin has no effect on human distal colonic motility, 589
Jennings, D. E. *see* Sanders, S. W.
Johnson, N. J. *see* Londong, W.
Jones, P. H. *see* Bell, G. D.
- Kaluba, J. *see* Holcombe, C.
Kammereit, A. *see* Madaus, S.
Kapadia, S. A. *see* Jameson, J. S.
Keane, C. *see* Patchett, S.
Keene, O. N. *see* Houghton, L. A.
Kemmer, T. P., Malfertheiner, P., Buchler, M., Friess, H., Meschenmoser, L., Ditschuneit, H., Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 209-995), 41
Kendall, M. J., Gibson, R., Walt, R. P., Co-administration of misoprostol or ranitidine with indomethacin: effects on pharmacokinetics, abdominal symptoms and bowel habit, 437
Kerr, G. D. *see* Green, J. R. B.
Khan, F. *see* Swift, G. L.
Kim, M. *see* Riley, S. A.
Klein, P. D. *see* Malaty, H.
Kleinert, R. *see* Hotz, J.
Koop, H., Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole, 399
Korman, M. *see* Pounder, R. E.
Kristensen, A. *see* Brenna, E.
Kromer, W. *see* Schuerer-Maly, C.-C.
- lactase deficiency*, 61
lactase malabsorption, 61
Lam, W. M. *see* Prewett, E. J.
Langholz, E., Brynskov, J., Bendtzen, K., Vilien, M., Binder, V., Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin, 495
lansoprazole, 87
Lastovica, A. *see* Young, G. P.
L'E Orme, M. *see* Grimmer, S. F. M.
Lecomte, J. M. *see* Bergmann, J. F.
Lennard-Jones, J. E. *see* Gertner, D. J.
Lennard-Jones, J. E. *see* Gaffer, M. H.
leucotrienes, 165
Levi, S. *see* Moss, S. F.
lignocaine, 739
lipid peroxidation, 671
lipoxygenase, 165
liquid emptying, 685
Londong, W., Phillips, J., Johnson, N. J., Wood, J. R., The effect of combined therapy with ranitidine and pirenzepine in the treatment of reflux oesophagitis, 609
Louchahi, K. *see* Petitjean, O.
Louv, J. A. *see* Young, G. P.
loxitidine, 335
Lucas, S. B. *see* Holcombe, C.
Luk, Y. W. *see* Prewett, E. J.
- McCarthy, P. T. *see* Jameson, J. S.
McColl, K. E. *see* Fullarton, G. M.
McCracken, K. H. *see* Morrison, G.
McIntyre, A. S., Thompson, D. G., Burnham, W. R., Walker, E., The effect of alpha-1-adrenoreceptor agonist and antagonist administration on human upper gastrointestinal transit and motility, 415
McIntyre, A. S., Thompson, D. G., Review article:

- adrenergic control of motor and secretory function in the gastrointestinal tract, 125
- McIntyre, P. B. *see* Gaffer, M. H.
- Madaus, S., Schulte-Frohlinde, E., Scherer, C., Kammerleit, A., Schusdziaar, V., Classen, M., Comparison of plasma bismuth levels after oral dosing with basic bismuth carbonate or tripotassium dicitrate bismuthate, 241
- magnesium salts, 447
- Mahida, Y. R. *see* Cole, A. T.
- maintenance therapy, 727
- maintenance treatment, 315, 479
- malabsorption, 399
- Malaty, H., Klein, P. D., Graham, D. Y., Short report: cefprozil for the eradication of *Helicobacter pylori* infection, 503
- Malfertheiner, P. *see* Kemmer, T. P.
- Malikova-Sekera, E. *see* Vatie, J.
- Manjunatha, S. *see* Gaffer, M. H.
- Marks, I. N. *see* Young, G. P.
- Matsuda, N. M. *see* Figueiredo, M. C. A.
- meal-stimulated, 189
- Melaraenge, R., Moore, G., Blower, P. R., Coates, M. E., Ward, F. W., Ronaasen, V., A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats, 67
- Meschenmoser, L. *see* Kemmer, T. P.
- Mesolazine, 261
- methionine, 231
- metronidazole, 113, 327, 427
- metronidazole sensitivity, 751
- metronidazole resistance, 427
- Mignon, M. *see* Vatie, J.
- Miller, P. F. *see* Uden, S.
- Mills, C. M. *see* Swift, G. L.
- Misiewicz, J. J. *see* Jameson, J. S.
- misoprostol, 437
- Modlin, I. M. *see* Young, G. P.
- monochloramine, 659
- monoclonal radioimmunoassay, 459
- Moore, G. *see* Melaraenge, R.
- Moore, J. G. *see* Sanders, S. W.
- Moreau, J. *see* Cortot, A.
- morning dosing, 381
- Morrison, G., Morrison, J. M., Redmond, A. O. B., Byers, C. A., McCracken, K. H., Dodge, J. A., Guilford, S. A., Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis, 549
- Morrison, J. M. *see* Morrison, G.
- Moss, S. F., Thomas, D. M., Ayesu, K., Levi, S., Calam, J., Sucralfate diminishes basal acid output without affecting gastrin, *H. pylori* or gastritis in duodenal ulcer patients, 257
- motilin receptors, 589
- motility, 273
- mucosal injury, 707
- multicentre trial, 609
- Nakaizumi, A. *see* Tatsuta, M.
- Nicolas, P. *see* Petitjean, O.
- nifadipine, 507
- night-time dosing, 381
- non-cardiac chest pain, 273
- non-ulcer dyspepsia, 119, 273, 291
- NSAIDs, 67, 717
- O'Brien, C. J. *see* Gaffer, M. H.
- octreotide, 41
- oesophageal emptying, 507
- oesophagitis, 565
- Okuda, S. *see* Tatsuta, M.
- Oliveira, R. B. *see* Figueiredo, M. C. A.
- Oliver, P. S. *see* Ford, G. A.
- omeprazole, 103, 181, 335, 399, 469, 565
- omeprazole (+ amoxycillin), 751
- O'Morain, C. *see* Patchett, S.
- ondansetron, 273
- opiate receptors, 305
- opioid peptides, 305
- oropharyngeal anaesthesia, 739
- Page, J. G. *see* Sanders, S. W.
- Pallecaros, A. *see* Bell, G. D.
- Pancrease HL, 549
- pancreatic secretion, 41
- pancreatic supplement, 549
- pantaprazole, 373
- Pappo, M. *see* Cortot, A.
- parietal cell, 335
- Patchett, S., Beattie, S., Keane, C., O'Morain, C., Short report: short-term triple therapy for *H. pylori*-associated duodenal ulcer disease, 113
- Patel, N., Ward, U., Rogers, M. J., Primrose, J. N., Night-time or morning dosing with H₂-receptor antagonists: studies on acid inhibition in normal subjects, 381
- pathogenesis, 659
- patient compliance, 181
- patients with reflux oesophagitis, 609
- Penston, J. G. *see* Boyd, E. J. S.
- Penston, J. G., Wormsley, K. G., Correspondence, 759
- Penston, J. G., Wormsley, K. G., Nine years of

- maintenance treatment with ranitidine for patients with duodenal ulcer disease, 629
 Penston, J. P. Wormsley, K. G., Review article: maintenance treatment with H_2 -receptor antagonists for peptic ulcer disease, 3
pepsinogen, 335
pepsinogen secretion, 171
peptic ulcer, 181, 291, 359
Pepto-Bismol, 97
 Perret, G. *see* Petitjean, O.
 Peterson, W. L. *see* Pounder, R. E.
 Petitjean, O., Wendling, J. L., Tod, M., Loughahi, K., Nicolas, P., Perret, G., Astier, A., Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis, 351
pharmacokinetics, 103, 357, 437, 459
pharmacotheapy, 521
phenylephrine, 415
 Phillips, J. *see* Londong, W.
plasma ethanol, 693
plasma gastrin, 389
plasma pepsinogen II, 389
 Polson, R. J. *see* Giasfer, M. H.
 Polson, R. J. *see* Jameson, J. S.
polyethylene glycol, 513
portal hypertension, 521
post-prandial ethyl alcohol, 269
 Postius, S. *see* Schuerer-Maly, C.-C.
potassium, 407
 Pounder, R. E. *see* Fraser, A. G.
 Pounder, R. E. *see* Prewett, E. J.
 Pounder, R. E., Festen, H., Korman, M., The long-term management of duodenal ulceration using an H_2 -antagonist: symptomatic self-care compared with maintenance treatment, 315
 Pounder, R. E., Peterson, W. L., A letter from the Editors, 1
 Powell, K. *see* Bell, G. D.
 Powell, K. *see* Weil, J.
 Powell, K. U. *see* Bell, G. D.
prednisolone, 31
 Prewett, E. J. *see* Fraser, A. G.
 Prewett, E. J., Luk, Y. W., Fraser, A. G., Lam, W. M., Pounder, R. E., Comparison of one-day oral dosing with three bismuth compounds for the suppression of *Helicobacter pylori* assessed by the ^{13}C -urea breath test, 97
primary biliary cirrhosis, 459
 Primrose, J. N. *see* Patel, N.
propylthiouracil, 541
 Prosser, S. *see* Bell, G. D.
prostaglandin production, 671
prostaglandins, 165
portal hypertension, 521
protein buffer, 447
proton pump, 291, 399
proton pump inhibitor, 87, 373
 Punchard, N. A. *see* Greenfield, S. M.
 Purser, K. *see* Bell, G. D.
 Quatrini, M. *see* Delle Fave, G.
radiopaque markers, 305
 Raimundo, A. H. *see* Jameson, J. S.
 Rampton, D. S. *see* Gertner, D. J.
randomised double-blind, 609
ranitidine, 181, 269, 437, 487, 597, 693, 707
ranitidine plus pirenzepine, 609
ranitidine plus pirenzepine placebo, 609
 Read, N. W. *see* Houghton, L. A.
rectal administration, 351
rectum, 165
recurrent pancreatitis, 231
 Redmond, A. O. B. *see* Morrison, G.
reflux oesophagitis, 181
renzapride, 273
 Rhodes, J. *see* Swift, G. L.
 Riley, S. A., Kim, M., Sutcliffe, F., Rowland, M., Turnberg, L. A., Absorption of polar drugs following caecal instillation in healthy volunteers, 701
 Robinson, M. *see* Roufail, W.
 Rodgers, W. H. *see* Bluhm, R. E.
 Rodrigues, C. A. *see* Giasfer, M. H.
 Rogers, J. *see* Jameson, J. S.
 Rogers, M. J. *see* Patel, N.
 Ronaasen, V. *see* Melarange, R.
 Rosalki, S. B. *see* Fraser, A. G.
Roter tablets, 97
 Roufail, W., Belsito, A., Robinson, M., Barish, C., Rubin, A., Glaxo Erosive Esophagitis Study Group, Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study, 597
 Rowland, M. *see* Riley, S. A.
 Rowlinson, A. *see* Green, J. R. B.
 Rubin, A. *see* Roufail, W.
salicylic acid, 701
salicylosulfapyridine, 165
 Samloff, I. M. *see* Fraser, A. G.
 Sanders, S. W., Moore, J. G., Day, G. M., Tolman, K. G., Circadian differences in pharmacological blockade of meal-stimulated gastric acid secretion, 187
 Sanders, S. W., Tolman, K. G., Greski, P. A., Jennings, D. E., Hoyos, P. A., Page, J. G., The effects of

- lansoprazole, a new H^+ , K^+ -ATPase inhibitor, on gastric pH and serum gastrin, 359
- sandostatin*, 41
- Sandvik, A. K. *see* Brenna, E.
- Sawyer, A. M. *see* Fraser, A. G.
- Schalm, S. W. *see* Beukers, R.
- Scherer, C. *see* Madaus, S.
- Schofield, D. *see* Uden, S.
- Schuerer-Maly, C.-C., Kromer, W., Flogerzi, B., Varga, L., Postius, S., Halter, F., Effect of acute and chronic acid suppression on plasma gastrin release in the rat, 195
- Schulte-Frohlinde, E. *see* Madaus, S.
- Schulze Sögnen, B. *see* Brenna, E.
- Schusdzia, V. *see* Madaus, S.
- Schwartz, J. C. *see* Bergmann, J. F.
- Schwarz, J. A. *see* Hotz, J.
- scleroderma*, 565
- selenium*, 231
- serotonin*, 273
- Shepherd, N. A. *see* Ford, G. A.
- short-term treatment*, 87
- side-effects*, 495
- Smith, M. *see* Fraser, A. G.
- SMS 201-995*, 41
- sodium picosulphate*, 513
- somatostatin*, 41
- Sorge, M. *see* Corazza, G. R.
- Soule, J. C. *see* Cortot, A.
- Spencer, G. *see* Bell, G. D.
- Stemmet, N. *see* Young, G. P.
- Stentoft, P. *see* Hendel, L.
- Stevens, T. R. J. *see* Gertner, D. J.
- Strocchi, A. *see* Corazza, G. R.
- sulcalfate*, 253
- sulphasalazine*, 51, 261
- sulphasalazine test*, 305
- Sutcliffe, F. *see* Riley, S. A.
- Swan, C. H. J. *see* Green, J. R. B.
- Swarbrick, E. T. *see* Green, J. R. B.
- Swift, G. L., Arnold, J., Williams, G. T., Williams, B. D., Rhodes, J., Khan, F., A comparison of upper gastrointestinal mucosal damage by standard and delayed-release indomethacin, 717
- Swift, G. L., Mills, C. M., Rhodes, J., Evans, B. K., Bennett, A., Tavares, I. A., A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine, 259
- sympathetic nerves*, 125, 253
- symptom relief*, 609
- symptomatic self-care*, 315
- Talley, N. J., Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation - clinical implications, 273
- Tatsuta, M., Iishi, H., Nakaizumi, A., Okuda, S., Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients, 221
- Tavares, I. A. *see* Swift, G. L.
- tetracycline*, 113
- therapeutic drug monitoring*, 209
- Thillainayagam, A. V. *see* Hunt, J. B.
- Thom, C. *see* Holcombe, C.
- Thomas, D. M. *see* Moss, S. F.
- Thompson, D. G. *see* McIntyre, A. S.
- Thompson, R. P. H. *see* Greenfield, S. M.
- Thornton, P. C. *see* Gaffner, M. H.
- Thornton, P. *see* Green, J. R. B.
- thymoxamine*, 415
- time factors*, 487
- Tjia, J. F. *see* Grimmer, S. F. M.
- Tod, M. *see* Petitjean, O.
- tolerance*, 51
- tolerance of endoscopy*, 739
- Tolman, K. G. *see* Sanders, S. W.
- Torsoli, A. *see* Delle Fave, G.
- transplant*, 209
- treatment*, 113, 119
- tripotassium dicitrato bismuthate*, 97, 113, 327, 751
- tripotassium dicitrato bismuthate in tetracycline*, 427
- trophic effect*, 335
- Trowell, J. E. *see* Bell, G. D.
- Turnberg, L. A. *see* Riley, S. A.
- Uden, S., Schofield, D., Miller, P. F., Day, J. P., Bottiglier, T., Braganza, J. M., Antioxidant therapy for recurrent pancreatitis: biochemical profiles in a placebo-controlled trial, 229
- ulcer relapse*, 87
- ulcerative colitis*, 31, 165, 479, 647
- ulcers*, 707
- urea*, 659
- urea breath test*, 503
- urease*, 659
- Van Den Berg, J. W. O. *see* Beukers, R.
- Van Den Merwe, E. L. *see* Young, G. P.
- Varga, L. *see* Schuerer-Maly, C.-C.
- Vatier, J., Malikova-Sekera, E., Vitre, M. T., Mignon, M., An artificial stomach-duodenum model for the in-vitro evaluation of antacids, 447
- verapamil*, 165
- Veyrac, M. *see* Cortot, A.

Vilien, M. *see* Langholz, E.

vitamin B₁₂, 399

vitamin C, 231

vitamin E, 231

Vitre, M. T. *see* Vatie, J.

Waldum, H. L. *see* Brenna, E.

Walker, E. *see* McIntyre, A. S.

Walt, R. P. *see* Hannan, A.

Walt, R. P. *see* Kendall, M. J.

Ward, F. W. *see* Melarange, R.

Ward, U. *see* Patel, N.

Washington, N., Greaves, J. L., Iftikhar, S. Y., A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension, 579

Weil, J. *see* Bell, G. D.

Weil, J. *see* Hannan, A.

Weil, J. Bell, G. D., Powell, K., Correspondence, 395

Wendling, J. L. *see* Petitjean, O.

Wilkinson, G. R. *see* Bluhm, R. E.

Wilkinson, S. P. *see* Ford, G. A.

Williams, B. D. *see* Swift, G. L.

Williams, G. T. *see* Swift, G. L.

Wood, J. R. *see* Londong, W.

Wormsley, K. G. *see* Boyd, E. J. S.

Wormsley, K. G. *see* Penston, J. G.

Wormsley, K. G. *see* Penston, J. P.

Young, G. P., Stemment, N., Lastovica, A., Van Den Merwe, E. L., Louw, J. A., Modlin, I. M., Marks, I. N., *Helicobacter pylori* lipopolysaccharide stimulates gastric mucosal pepsinogen secretion, 169

zacopride, 273